PFIZER INC Net Cash Provided by (Used in) Investing Activities, Continuing Operations
PFIZER INC (PFE) reported Net Cash Provided by (Used in) Investing Activities, Continuing Operations of -$32.28 billion for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-22.
Discontinued › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations · last filed 2024-02-22
- PFIZER INC net cash provided by (used in) investing activities, continuing operations for the quarter ending 2022-12-31 was -$4.41B.
- PFIZER INC net cash provided by (used in) investing activities, continuing operations for the quarter ending 2022-10-02 was -$627.00M.
- PFIZER INC net cash provided by (used in) investing activities, continuing operations for the quarter ending 2022-07-03 was -$11.31B.
- PFIZER INC net cash provided by (used in) investing activities, continuing operations for the quarter ending 2022-04-03 was $567.00M.
- PFIZER INC net cash provided by (used in) investing activities, continuing operations for fiscal 2023 was -$32.28B.
- PFIZER INC net cash provided by (used in) investing activities, continuing operations for fiscal 2022 was -$15.78B.
- PFIZER INC net cash provided by (used in) investing activities, continuing operations for fiscal 2021 was -$22.53B.
- PFIZER INC net cash provided by (used in) investing activities, continuing operations for fiscal 2020 was -$4.16B.
| Period end | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 3 month as first filed | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 6 month as first filed | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 9 month as first filed | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 12 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2023-12-31 | -$32.28B 10-K · filed 2024-02-22 | |||||||
| 2022-12-31 | -$4.41B derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | -$5.04B derived: sum of 2 quarters · filed 2024-02-22 | -$16.35B derived: sum of 3 quarters · filed 2024-02-22 | -$15.78B 10-K · filed 2024-02-22 | ||||
| 2022-10-02 | -$627.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | -$11.94B derived: sum of 2 quarters · filed 2022-11-09 | -$11.37B 10-Q · filed 2022-11-09 | -$13.96B derived: sum of 4 quarters · filed 2024-02-22 | ||||
| 2022-07-03 | -$11.31B derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | -$10.75B 10-Q · filed 2022-08-10 | -$13.33B derived: sum of 3 quarters · filed 2024-02-22 | -$23.40B derived: sum of 4 quarters · filed 2024-02-22 | ||||
| 2022-04-03 | $567.00M 10-Q · filed 2022-05-11 | -$2.02B derived: sum of 2 quarters · filed 2024-02-22 | -$12.09B derived: sum of 3 quarters · filed 2024-02-22 | -$20.22B derived: sum of 4 quarters · filed 2024-02-22 | ||||
| 2021-12-31 | -$2.58B derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | -$12.65B derived: sum of 2 quarters · filed 2024-02-22 | -$20.79B derived: sum of 3 quarters · filed 2024-02-22 | -$22.53B 10-K · filed 2024-02-22 | ||||
| 2021-10-03 | -$10.07B derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | -$18.20B derived: sum of 2 quarters · filed 2022-11-09 | -$19.95B 10-Q · filed 2022-11-09 | -$19.96B 10-Q · filed 2021-11-12 | -$22.98B derived: sum of 4 quarters · filed 2023-02-23 | |||
| 2021-07-04 | -$8.13B derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | -$9.88B 10-Q · filed 2022-08-10 | -$9.88B 10-Q · filed 2021-08-12 | -$12.91B derived: sum of 3 quarters · filed 2023-02-23 | -$12.41B derived: sum of 4 quarters · filed 2023-02-23 | |||
| 2021-04-04 | -$1.75B 10-Q · filed 2022-05-11 | -$1.75B 10-Q · filed 2021-05-13 | -$4.78B derived: sum of 2 quarters · filed 2023-02-23 | -$4.28B derived: sum of 3 quarters · filed 2023-02-23 | -$5.86B derived: sum of 4 quarters · filed 2023-02-23 | |||
| 2020-12-31 | -$3.03B derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | -$2.53B derived: sum of 2 quarters · filed 2023-02-23 | -$4.11B derived: sum of 3 quarters · filed 2023-02-23 | -$4.16B 10-K · filed 2023-02-23 | -$4.19B 10-K · filed 2021-02-25 | |||
| 2020-09-27 | $501.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | -$1.08B derived: sum of 2 quarters · filed 2021-11-12 | -$1.13B 10-Q · filed 2021-11-12 | |||||
| 2020-06-28 | -$1.58B derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | -$1.63B 10-Q · filed 2021-08-12 | ||||||
| 2020-03-29 | -$53.00M 10-Q · filed 2021-05-13 | |||||||
| 2019-12-31 | -$3.83B 10-K · filed 2022-02-24 | -$3.85B 10-K · filed 2021-02-25 | ||||||
| 2018-12-31 | $4.58B 10-K · filed 2021-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |